15. December 2021

ARQIS has advised biotech company Emergence Therapeutics AG on a Series A financing round of 87 million euro.

The round was led by Pontifax Venture Capital and includes the existing, as well as certain new investors. Emergence Management also participated in the round. Proceeds from this funding round will be used to advance the company’s next-generation antibody drug conjugate (ADC) targeting Nectin-4 to clinical proof-of-concept as well as the development of additional ADC programs. Antibody drug conjugates are among the most promising areas of research in the fight against cancer.

Emergence is based in Duisburg, Germany with a subsidiary in Marseille, France. According to statistics from the industry association Bio Deutschland, this round is the largest Series A round in the biotech industry to date.

The ARQIS team around partner Dr. Christof Alexander Schneider has been advising Emergence Therapeutics since its foundation in 2019 and already assisted with all the preceding financing rounds.

Advisors to Emergence Therapeutics

ARQIS (Dusseldorf/Munich): Dr. Christof Alexander Schneider (Leading Partner), Dr. Mauritz von Einem (both Corporate/ Venture Capital) Counsel: Friedrich Gebert (Regulatory); Associate: Louisa Theresa Graf (Corporate/ Venture Capital); Legal Specialist: Hannah Potter (Corporate/ Venture Capital)